D.E. Shaw & Co
ARCT icon

D.E. Shaw & Co’s Arcturus Therapeutics ARCT Stock Holding History

D.E. Shaw & Co’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.64M Buy
392,358
+140,324
+56% +$1.11M ﹤0.01% 2961
2026
Q1 		$1.95M Buy
252,034
+154,211
+158% +$1.13M ﹤0.01% 2938
2025
Q4 		$600K Buy
97,823
+37,610
+62% +$406K ﹤0.01% 3844
2025
Q3 		$1.11M Buy
60,213
+49,776
+477% +$800K ﹤0.01% 3395
2025
Q2 		$136K Buy
+10,437
New +$123K ﹤0.01% 4093
2024
Q2 		– Sell
-10,355
Closed -$350K – 4472
2024
Q1 		$350K Sell
10,355
-63,440
-86% -$2.25M ﹤0.01% 3662
2023
Q4 		$2.33M Buy
73,795
+29,166
+65% +$693K ﹤0.01% 2548
2023
Q3 		$1.14M Sell
44,629
-57,458
-56% -$1.77M ﹤0.01% 2984
2023
Q2 		$2.93M Buy
+102,087
New +$2.78M ﹤0.01% 2315
2022
Q1 		– Sell
-128,363
Closed -$4.75M – 5503
2021
Q4 		$4.75M Buy
128,363
+32,597
+34% +$1.33M ﹤0.01% 2427
2021
Q3 		$4.58M Sell
95,766
-209,324
-69% -$9.38M ﹤0.01% 2189
2021
Q2 		$10.3M Buy
305,090
+225,152
+282% +$7.62M 0.01% 1473
2021
Q1 		$3.3M Buy
+79,938
New +$4.77M ﹤0.01% 2162
2020
Q3 		– Sell
-5,874
Closed -$275K – 3810
2020
Q2 		$275K Buy
+5,874
New +$202K ﹤0.01% 3658
2017
Q2 		– Sell
-19,745
Closed -$158K – 3352
2017
Q1 		$158K Buy
19,745
+11,993
+155% +$111K ﹤0.01% 3156
2016
Q4 		$114K Buy
7,752
+3,098
+67% +$46.3K ﹤0.01% 3335
2016
Q3 		$80K Sell
4,654
-13,519
-74% -$437K ﹤0.01% 3299
2016
Q2 		$571K Buy
18,173
+946
+5% +$29.8K ﹤0.01% 2732
2016
Q1 		$457K Buy
17,227
+2,931
+21% +$99.2K ﹤0.01% 2827
2015
Q4 		$628K Buy
14,296
+9,935
+228% +$447K ﹤0.01% 2939
2015
Q3 		$184K Buy
4,361
+2,710
+164% +$143K ﹤0.01% 3513
2015
Q2 		$76K Sell
1,651
-5,520
-77% -$253K ﹤0.01% 3668
2015
Q1 		$283K Buy
7,171
+1,150
+19% +$50.6K ﹤0.01% 3326
2014
Q4 		$157K Buy
+6,021
New +$191K ﹤0.01% 3851

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

D.E. Shaw & Co's ARCT Position: Q2 2026 in Review

D.E. Shaw & Co increased its Arcturus Therapeutics (ARCT) stake by 56% in Q2 2026, buying an estimated $1.11M and bringing the position to 392,358 shares worth $2.64M. The position accounts for ﹤0.01% of the portfolio, ranked #2961.

D.E. Shaw & Co first reported a position in ARCT in Q4 2014 and has held it in 24 quarters since. The position peaked at $10.3M in Q2 2021. 135 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

  • D.E. Shaw & Co held 392,358 shares of Arcturus Therapeutics worth $2.64M as of Q2 2026.
  • D.E. Shaw & Co bought 140,324 Arcturus Therapeutics shares in Q2 2026, an estimated $1.11M.
  • Arcturus Therapeutics made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #2961 holding.
  • D.E. Shaw & Co first reported a position in Arcturus Therapeutics in Q4 2014 and has held it in 24 quarters since.
  • D.E. Shaw & Co's Arcturus Therapeutics position peaked at $10.3M in Q2 2021.
  • 135 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.